ReviewAging cell2026
Genome Aging in Women: Hematopoietic Loss of X Chromosome as An Exemplar.
Review in Aging cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Genome aging refers to age-related acquisition and expansion of de novo mutations in somatic cells, and is now increasingly viewed as a central driver of organismal aging. Loss of X chromosome (LOX), the state in which one X chromosome (ChrX) is missing, represents the most common genetically inferred type of acquired mutation in women. Recent technological advancements, along with the growing availability of large-scale cohorts for association studies, have provided powerful new insights into this phenomenon. The frequency and clone size of LOX increase significantly with age: with over 10% of women aged 55 years or older showing detectable LOX in blood. LOX preferentially affects the inactivated ChrX derived from either parent, or in some cases, affects the ChrX from one specific parent. Besides aging, the acquisition and expansion of LOX are shaped by factors related to ChrX itself, genome-wide inherited and acquired variants, and lifestyle and environmental stressors. Due to the critical biological roles of ChrX, even in its inactive state, LOX impairs cellular functions and is strongly linked to hematological malignancies and a range of benign diseases. Understanding the mechanisms driving the causes and consequences of LOX may expand the sex-biased genomic architecture of aging and uncover strategies for disease prevention in women. In this review, by integrating the most recent progress in LOX studies with unique biology of ChrX and perspectives from aneuploidy, we provide a synthesized and updated understanding of the rise, expansion and consequences of blood LOX, while also posing key questions for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.